Do IMNM Antibody Levels Correlate With Disease Activity?
At a Glance
IMNM antibody levels can decline with treatment but do not reliably reflect day-to-day disease activity. Doctors usually assess CK trends, muscle strength, symptoms, and sometimes MRI to determine whether muscle injury is active and treatment is working.
In this answer
4 sections
While your anti-HMGCR or anti-SRP antibody levels may decrease as your immunosuppressive treatment starts working, they do not perfectly match your day-to-day disease activity [1][2]. Many patients experience significant clinical improvement and regain their strength even though their antibody tests remain positive [1]. Because of this, doctors do not rely on driving your antibody levels to zero to determine if your treatment is successful. Instead, they focus on tracking your creatine kinase (CK) levels and conducting physical strength assessments to guide your care [3][4].
(Note: Not everyone with IMNM has these autoantibodies. Some patients have antibody-negative, or seronegative, IMNM. If you do not have anti-HMGCR or anti-SRP antibodies, this specific section on antibody tracking may not apply to you, though the information on CK and strength remains relevant).
Why Antibody Levels Can Be Misleading
In Immune-Mediated Necrotizing Myopathy (IMNM), your immune system produces autoantibodies that mistakenly identify specific muscle-associated proteins as threats.
When you start immunosuppressive therapy, the autoimmune response is suppressed or redirected. As a result, the measured amount of these autoantibodies in your blood (your antibody titer) may decrease [1][2]. In some cases, such as in certain patients with statin-associated IMNM, anti-HMGCR antibodies may even become undetectable [5].
However, the relationship between your measured antibody levels and actual muscle injury is not simple. For example, in one study of patients with anti-HMGCR antibodies, 83% remained antibody-positive despite receiving treatment [1]. Other small studies have shown that some patients who are in clinical remission with normal strength continue to have persistently elevated anti-HMGCR antibody titers for years [6][7]. Furthermore, checking your antibody level at a single point in time has been shown to correlate poorly with the actual amount of muscle damage occurring at that moment [1].
For these reasons, a single positive antibody result is primarily used to help diagnose and classify the disease, rather than as a reliable standalone test to monitor day-to-day or week-to-week disease activity.
The Role of Creatine Kinase (CK)
Rather than frequently checking your antibody levels, your care team will regularly monitor your creatine kinase (CK) trends as one important measure of disease activity [3].
CK is an enzyme found inside your muscle cells. When your muscles are actively injured, the cells break open and leak CK into your bloodstream.
- A high CK level may indicate recent or ongoing muscle injury. However, it must be interpreted in context, as CK can also be elevated by strenuous exercise, falls, injections, or other medications.
- A dropping CK trend suggests that the active immune-mediated muscle injury is slowing down and your treatment may be working [3][8].
While CK is highly useful, it is not a perfect, real-time measure. It can sometimes lag behind your actual symptoms, which is why doctors look at the trend over time rather than reacting to a single abnormal number.
The Importance of Physical Strength Assessments
While blood tests like CK are crucial, they do not tell the whole story. Your doctor will also rely heavily on regular physical examinations to test your muscle strength and function [4].
Sometimes, blood work and physical strength do not perfectly align:
- Low or normal CK but lingering weakness: You might have normal or near-normal CK levels but still feel weak [9]. This persistent weakness does not automatically mean the IMNM is highly active; it can occur because damaged muscle tissue takes time to rebuild, or because some muscle has been permanently replaced by fat [10]. It can also be caused by physical deconditioning, ongoing lower-level disease activity, or side effects from medications like steroids.
- Elevated CK but good strength: Conversely, some patients regain near-full or full strength while their CK levels remain somewhat elevated [11].
Because IMNM is distinct from other muscle diseases—often causing severe muscle cell death (necrosis) with very little visible inflammation [12]—your doctor will use a combination of your CK trends, your reported symptoms, and hands-on strength tests to decide if your medication needs adjustment [13][4].
When to Seek Urgent Care
Safety Note: While gradual changes in strength are common, you should contact your care team promptly if you experience rapidly worsening weakness, or repeated falls. Seek urgent or emergency medical care if you develop new trouble swallowing, choking, or difficulty breathing, as these can signal clinically dangerous muscle involvement [14].
Comparing Your Monitoring Tools
| Tool | What It Tells You | What It Cannot Tell You |
|---|---|---|
| Antibody Titers | Helps diagnose the type of IMNM; may decrease over time with treatment. | Does not reliably measure day-to-day muscle damage; can remain positive even when you are in remission. |
| CK Levels | A dropping trend often indicates that active muscle injury is slowing down. | Can be elevated by exercise or falls; a normal CK does not guarantee that your strength has fully returned. |
| Physical Strength Assessments | Shows how well you can perform daily tasks (like standing up, climbing stairs, lifting arms). | Does not distinguish between active immune damage and permanent muscle loss on its own. |
| Muscle MRI (when indicated) | Can show areas of active muscle swelling (edema) or chronic fat replacement. | Is typically not used for routine, frequent monitoring due to cost and access. |
Common questions in this guide
Do anti-HMGCR or anti-SRP antibody levels show how active IMNM is?
What tests are most useful for tracking IMNM activity?
Can I still be weak if my CK level is normal?
Does a positive IMNM antibody test mean my disease is still active?
When should I seek urgent help for IMNM symptoms?
Related questions
Show more
Get notified when new evidence is published on Immune-mediated necrotizing myopathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
Clinical associations of patients with anti-3-hydroxy-3-methylglutaryl CoA reductase antibody-associated immune-mediated necrotising myopathy.
Tan E, Knight J, Khonasti S, et al.
Internal medicine journal 2023; (53(10)):1846-1853 doi:10.1111/imj.16004.
PMID: 36625419 - 2
Treatment of refractory immune-mediated necrotizing myopathy with efgartigimod.
Yang M, Yuan J, Wang Y, et al.
Frontiers in immunology 2024; (15()):1447182 doi:10.3389/fimmu.2024.1447182.
PMID: 39502686 - 3
Immune-mediated necrotizing myopathies: clinico-serological features and treatment outcomes of a large Italian cohort of patients.
Bonanno S, Salvi E, Cheli M, et al.
Journal of neurology 2026; (273(9)).
PMID: 42671644 - 4
Management of immune-mediated necrotizing myopathy.
Suh J, Amato AA
Muscle & nerve 2024; (70(2)):166-172 doi:10.1002/mus.28114.
PMID: 38801022 - 5
Clinico-serologic features of statin-induced necrotising autoimmune myopathy in a single-centre cohort.
Waters MJ, Limaye V
Clinical rheumatology 2018; (37(2)):543-547 doi:10.1007/s10067-017-3831-2.
PMID: 28905130 - 6
Spontaneous remission in statin-associated HMGCR-positive immune-mediated necrotizing myopathy after statin withdrawal.
Mossakowski AA, Pascale D, Allenbach Y, et al.
Neuromuscular disorders : NMD 2026; (60()):106367 doi:10.1016/j.nmd.2026.106367.
PMID: 41650628 - 7
Spontaneous symptomatic improvement in a pediatric patient with anti-3-hydroxy-3-methylglutraryl-coenzyme A reductase myopathy.
Suárez B, Jofré J, Lozano-Arango A, et al.
Neuromuscular disorders : NMD 2020; (30(6)):503-509 doi:10.1016/j.nmd.2020.03.008.
PMID: 32518057 - 8
Unusual cases of Anti-SRP necrotizing myopathy with predominant distal leg weakness and atrophy.
Moshe-Lilie O, Ghetie D, Banks G, et al.
Neuromuscular disorders : NMD 2022; (32(2)):170-175 doi:10.1016/j.nmd.2021.11.010.
PMID: 35031192 - 9
Benefits of Early Versus Late Initiation of Intravenous Immunoglobulin in the Treatment of Patients With Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Immune-Mediated Necrotizing Myopathy.
Sharf K, Do T, Ghetie D, et al.
Arthritis care & research 2024; (76(11)):1584-1592 doi:10.1002/acr.25406.
PMID: 39054727 - 10
Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity.
Pinal-Fernandez I, Casal-Dominguez M, Carrino JA, et al.
Annals of the rheumatic diseases 2017; (76(4)):681-687 doi:10.1136/annrheumdis-2016-210198.
PMID: 27651398 - 11
Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle.
Pinal-Fernandez I, Parks C, Werner JL, et al.
Arthritis care & research 2017; (69(2)):263-270 doi:10.1002/acr.22920.
PMID: 27111848 - 12
Persistent HyperCKemia Beyond Post-Viral Myositis: A Case of Anti-HMGCR Immune-Mediated Necrotizing Myopathy.
Xavier R, Silva S, Cunha R, et al.
Cureus 2026; (18(9)):e116203 doi:10.7759/cureus.116203.
PMID: 42877551 - 13
Therapeutic management of immune-mediated necrotizing myositis.
Weeding E, Tiniakou E
Current treatment options in rheumatology 2021; (7(2)):150-160 doi:10.1007/s40674-021-00174-1.
PMID: 34422547 - 14
The Characteristics of Imaging Patterns on Whole-body Magnetic Resonance Imaging of Anti-signal Recognition Particle Antibody-positive Immune-mediated Necrotizing Myopathy.
Hou YY, Huang WC, Huang CR, et al.
Acta neurologica Taiwanica 2025; (34(4)):216-223 doi:10.4103/ANT.ANT_113_0054.
PMID: 41467261
This page explains how clinicians monitor IMNM for educational purposes and does not replace medical advice. Ask your neurologist or rheumatologist how your CK, strength, symptoms, and antibody results apply to your care.